Henlius ACE2-Fc receptor fusion protein HLX71 Phase I clinical results are positive

Henlius announced that its self-developed ACE2-Fc receptor fusion protein HLX71 has recently completed a Phase 1 clinical study, demonstrating good safety and tolerance in a Phase 1 clinical study in healthy adult subjects.
acceptability
.
It is reported that HLX71 is a self-developed recombinant human Angiotensin converting enzyme 2 (hACE2) fusion protein with IgG1 Fc at the C-terminus, which is intended for the treatment of novel coronavirus pneumonia (COVID-19)
.
Its mechanism of action is that HLX71 can competitively bind to the Spike protein on the surface of SARS-CoV-2, thereby inhibiting the binding of the virus to angiotensin converting enzyme 2 (ACE2) on the surface of host cells, and ultimately inhibiting viral infection.
effect
.
Preclinical pharmacology studies, pharmacokinetic studies and safety evaluation have proved that HLX71 can significantly inhibit SARS-CoV-2 virus infection, has good safety, and can be used for subsequent human clinical trials
.
In November 2020, the U.
S.
Food and Drug Administration (FDA) approved the clinical trial application (IND) of HLX71 for the treatment of novel coronavirus pneumonia (COVID-19)
.